SRPT Q4 2019 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$100M+18.6% YoY

Gross Profit

$85M84.5% margin

Operating Income

-$230M-230.0% margin

Net Income

-$236M-235.4% margin

EPS (Diluted)

$-3.19

QoQ Revenue Growth

+1.1%

Cash Flow

Operating Cash Flow

-$164M

Free Cash Flow

-$182M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$1.0B

Stockholders' Equity

$818M

Cash & Equivalents

$835M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$100M	$84M	+18.6%
Gross Profit	$85M	$71M	+18.6%
Operating Income	-$230M	-$139M	-65.2%
Net Income	-$236M	-$141M	-67.3%